Fig. 4
From: MiR-23b controls ALDH1A1 expression in cervical cancer stem cells
MiR-23b confers cisplatin sensitivity to cervical cancer cells. a-b. Introduction of miR-23b into Hela cells a and CaSki cells b sensitized cells to cisplatin treatment. c-d. Addition of miR-23b inhibitor into Hela cells c and CaSki cells d makes cells more resistant to cisplatin treatment. Data is presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001